Log In
Print this Print this

Odefsey, Rilpivirine/emtricitabine/tenofovir alafenamide

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionSingle-tablet regimen combining rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI), emtricitabine, an NRTI, and tenofovir alafenamide, a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir
Molecular Target HIV reverse transcriptase
Mechanism of ActionHIV reverse transcriptase inhibitor; Nucleoside analog reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection in patients ages >=12
Regulatory Designation U.S. - Priority Review (Treat HIV-1 infection in patients ages >=12)
PartnerGilead Sciences Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today